Introduction
============

Hypertension is a complex multifactorial disorder that is thought to result from an interaction between an individual's genetic background and various lifestyle and environmental factors ([@b1-ijmm-35-05-1189]). The genetic influence on blood pressure (BP) variability has been estimated at 30--60% for a given individual ([@b2-ijmm-35-05-1189]), and the genetic heritability of hypertension estimated at 30% ([@b3-ijmm-35-05-1189]). Given that hypertension is a major risk factor for coronary artery disease, ischemic and hemorrhagic stroke, as well as chronic kidney disease ([@b4-ijmm-35-05-1189]--[@b6-ijmm-35-05-1189]), the personalized prevention of hypertension is an important public health goal.

Genome-wide association studies have identified various loci and genes associated with BP or to a predisposition to hypertension in Caucasian populations ([@b7-ijmm-35-05-1189]--[@b11-ijmm-35-05-1189]) or African Americans ([@b12-ijmm-35-05-1189]). Although the genes for adducin 2 ([@b13-ijmm-35-05-1189]) and ATPase, Ca^2+^ transporting, plasma membrane 1 ([@b14-ijmm-35-05-1189]) have been shown to be susceptibility loci for hypertension in Japanese individuals, the genes that confer susceptibility to this condition in Japanese individuals remain to be identified definitively.

We have previously identified 9 genes and chromosomal region 3q28 as susceptibility loci for myocardial infarction, ischemic stroke, or chronic kidney disease in Japanese individuals by genome-wide ([@b15-ijmm-35-05-1189]--[@b17-ijmm-35-05-1189]) or candidate gene ([@b18-ijmm-35-05-1189]--[@b20-ijmm-35-05-1189]) association studies. Given that hypertension is an important risk factor for these conditions ([@b4-ijmm-35-05-1189]--[@b6-ijmm-35-05-1189]), we hypothesized that certain single nucleotide polymorphisms (SNPs) at these 10 loci may contribute to their genetic susceptibility by affecting the susceptibility to hypertension. Therefore, the purpose of the present study was to examine the possible association of 13 SNPs at these 10 loci with the prevalence of essential hypertension or their association with BP in community-dwelling Japanese individuals.

Materials and methods
=====================

Study population
----------------

Study subjects comprised 6,027 community-dwelling individuals (2,250 subjects with essential hypertension and 3,777 controls) who were recruited to a population-based cohort study in Inabe City (Inabe Health and Longevity Study), Mie Prefecture, Japan. The Inabe Health and Longevity Study is a longitudinal genetic epidemiological study of atherosclerotic, cardiovascular and metabolic diseases ([@b21-ijmm-35-05-1189]--[@b26-ijmm-35-05-1189]). The subjects were recruited from individuals who visited the Health Care Center of Inabe General Hospital for an annual health checkup, and they are followed up each year. A total of 6,027 individuals was registered between March 2010 and September 2012, and genomic DNA was extracted from the venous blood cells of these subjects and stored in the genomic DNA bank of the Research Center for Genomic Medicine at Mie University. For all the participants, medical examination data obtained from April 2003 to March 2014 (11 years) were entered into a database. If individuals had a medical checkup 2 or more times per year, data from one time point for each year were entered, so that each subject had one set of health data for each year they had attended the clinic. All participants thus had undergone 1--11 medical examinations, and the average follow-up period was 5 years.

Subjects with hypertension either had a systolic BP of ≥140 mmHg or a diastolic BP of ≥90 mmHg (or both) or had taken anti-hypertensive medication. The control individuals had a systolic BP of \<140 mmHg and a diastolic BP of \<90 mmHg, as well as no history of hypertension or of taking any anti-hypertensive medication. BP was measured at least twice with the subjects having rested in the sitting position for \>5 min; the measurements were taken by a skilled physician or nurse according to the guidelines of the American Heart Association ([@b27-ijmm-35-05-1189]). The study protocol complied with the Declaration of Helsinki and was approved by the Committees on the Ethics of Human Research of Mie University Graduate School of Medicine and Inabe General Hospital. Written informed consent was obtained from all subjects prior to enrollment in the study.

Selection and genotyping of polymorphisms
-----------------------------------------

The 13 SNPs examined in the present study ([Table I](#tI-ijmm-35-05-1189){ref-type="table"}) were selected from our previous genome-wide ([@b15-ijmm-35-05-1189]--[@b17-ijmm-35-05-1189]) or candidate gene ([@b18-ijmm-35-05-1189]--[@b20-ijmm-35-05-1189]) association studies. Wild-type (ancestral) and variant alleles of the SNPs were determined from the dbSNP database (National Center for Biotechnology Information, Bethesda, MD, USA) (<http://www.ncbi.nlm.nih.gov/SNP>).

Venous blood (5 ml) was collected into tubes containing 50 mmol/l ethylenediaminetetraacetic acid (disodium salt), and peripheral blood leukocytes were isolated and genomic DNA was extracted from these cells with the use of a DNA extraction kit (SMITEST EX-R&D; Medical and Biological Laboratories, Nagoya, Japan). The genotypes of the 13 SNPs were determined at G&G Science Co., Ltd. (Fukushima, Japan) by a method that combines the polymerase chain reaction and sequence-specific oligonucleotide probes with suspension array technology (Luminex, Austin, TX, USA). The primers, probes and other conditions for the genotyping of the SNPs examined in the present study are shown in [Table II](#tII-ijmm-35-05-1189){ref-type="table"}. Detailed genotyping methodology was as described previously ([@b15-ijmm-35-05-1189],[@b16-ijmm-35-05-1189],[@b28-ijmm-35-05-1189]).

Statistical analysis
--------------------

Quantitative data were compared between the subjects with hypertension and the controls with the unpaired Student's t-test. Categorical data were compared with the χ^2^ test. We examined the association of the 13 SNPs with the prevalence of hypertension or their association with systolic, diastolic, or mean BP based on a 5-year longitudinal cohort study. Longitudinal changes in the prevalence of hypertension were compared between 2 groups (the dominant or recessive genetic model) with a generalized estimating equation, as previously described ([@b29-ijmm-35-05-1189]) and with adjustment for age, gender, body mass index (BMI) and smoking status. Longitudinal changes in systolic, diastolic, or mean BP in all the individuals or in the individuals not any taking anti-hypertensive medication were compared between 2 groups (the dominant or recessive model) in a generalized linear mixed-effect model, as previously described ([@b30-ijmm-35-05-1189]) with adjustment for age, gender, BMI and smoking status. The dominant or recessive model was defined as *AA* vs. *AB* + *BB* or *AA* + *AB* vs. *BB* (*A*, major allele; *B*, minor allele), respectively. Age-related changes in the prevalence of hypertension or in systolic or diastolic BP were estimated with quadratic curves controlling for the observation year. A P-value \<0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed using R software version 3-0-2 (the R Project for Statistical Computing) and JMP Genomics version 6.0 (SAS Institute, Cary, NC, USA).

Results
=======

Characteristics of the 6,027 study subjects (3,352 males, 2,675 females) with regard to all measurements in a 5-year follow-up are shown in [Table III](#tIII-ijmm-35-05-1189){ref-type="table"}. Characteristics of the subjects with hypertension and the controls according to cross-sectional analysis in March 2014 are shown in [Table IV](#tIV-ijmm-35-05-1189){ref-type="table"}. Age, the frequency of the male gender, BMI and the prevalence of smoking were greater in the subjects with hypertension than in the controls.

The association of the 13 SNPs with the prevalence of hypertension was analyzed with a generalized estimating equation and with adjustment for age, gender, BMI and smoking status ([Table V](#tV-ijmm-35-05-1189){ref-type="table"}). The rs2116519 (C→T) SNP of the family with sequence similarity 78, member B gene (*FAM78B*, recessive model), rs6929846 (T→C) of the butyrophilin, subfamily 2, member A1 gene (*BTN2A1*, dominant model), rs146021107 (G→-) of the pancreatic and duodenal homeobox 1 gene (*PDX1*, dominant model) and rs1671021 (G→A) of the lethal giant larvae homolog 2 gene (*LLGL2*, dominant model) were significantly (P\<0.05) associated with the prevalence of hypertension.

The association between the prevalence of hypertension and age analyzed longitudinally with a generalized estimating equation according to the SNP genotype is shown in [Fig. 1](#f1-ijmm-35-05-1189){ref-type="fig"}. The prevalence of hypertension was greater in the combined group of subjects with the *TT* or *TC* genotypes of rs2116519 of *FAM78B* than in those with the *CC* genotype from 40 to 90 years of age ([Fig. 1A](#f1-ijmm-35-05-1189){ref-type="fig"}), in the combined group of subjects with the *CT* or *TT* genotypes of rs6929846 of *BTN2A1* than in those with the *CC* genotype ([Fig. 1B](#f1-ijmm-35-05-1189){ref-type="fig"}), in subjects with the *GG* genotype of rs146021107 of *PDX1* than in the combined group of subjects with the *G/*- or -/- genotypes ([Fig. 1C](#f1-ijmm-35-05-1189){ref-type="fig"}), and in the combined group of subjects with the *AG* or *GG* genotypes of rs1671021 of *LLGL2* than in those with the *AA* genotype ([Fig. 1D](#f1-ijmm-35-05-1189){ref-type="fig"}).

Given that 4 SNPs were significantly associated with hypertension, the association of these SNPs with systolic, diastolic, or mean BP in all individuals or individuals not taking any anti-hypertensive medication were analyzed with a generalized linear mixed-effect model, with adjustment for age, gender, BMI and smoking status ([Table VI](#tVI-ijmm-35-05-1189){ref-type="table"}). The rs6929846 polymorphism of *BTN2A1* was significantly associated with systolic, diastolic and mean BP in the dominant model among all individuals or individuals not taking any anti-hypertensive medication, with the *T* allele being associated with an increased BP. The rs146021107 SNP of *PDX1* was significantly associated with systolic BP in the dominant model among all individuals or individuals not taking any anti-hypertensive medication, with the *G* allele being associated with an increased BP. The rs2116519 polymorphism of *FAM78B* was significantly associated with diastolic BP in the recessive model among individuals not taking any anti-hypertensive medication, with the *T* allele being associated with a high BP. The rs1671021 SNP of *LLGL2* was significantly associated with diastolic and mean BP in the dominant model among individuals not taking any anti-hypertensive medication, with the *G* allele being associated with a high BP.

The association between systolic or diastolic BP and age in individuals not taking any anti-hypertensive medication was analyzed longitudinally according to genotype with a generalized linear mixed-effect model ([Fig. 2](#f2-ijmm-35-05-1189){ref-type="fig"}). Systolic ([Fig. 2A](#f2-ijmm-35-05-1189){ref-type="fig"}) and diastolic ([Fig. 2B](#f2-ijmm-35-05-1189){ref-type="fig"}) BP were greater in the combined group of individuals with the *CT* or *TT* genotypes of rs6929846 of *BTN2A1* than in those with the *CC* genotype from 40 to 90 years of age. Systolic BP was greater in subjects with the *GG* genotype of rs146021107 of *PDX1* than in the combined group of individuals with the *G/*- or -/- genotypes ([Fig. 2C](#f2-ijmm-35-05-1189){ref-type="fig"}). Diastolic BP was greater in the combined group of individuals with the *AG* or *GG* genotypes of rs1671021 of *LLGL2* than in those with the *AA* genotype ([Fig. 2D](#f2-ijmm-35-05-1189){ref-type="fig"}).

Discussion
==========

Given that genetic factors, as well as interactions between multiple genes and environmental factors are important in the development of hypertension ([@b1-ijmm-35-05-1189]), the ability to predict the risk of developing hypertension on the basis of genetic variants would be beneficial for the personalized prevention of this condition. In this study, we demonstrated that rs6929846 (T→C) of *BTN2A1* was significantly associated with the prevalence of hypertension and also with systolic, diastolic, and mean BP in community-dwelling Japanese individuals, with the minor *T* allele representing a risk factor for hypertension.

We have previously reported that rs6929846 of *BTN2A1* is significantly associated with hypertension in a cross-sectional study of a different hospital-based population ([@b31-ijmm-35-05-1189]). We also observed the association of this polymorphism with hypertension in a previous cross-sectional analysis of the Inabe Health and Longevity Study ([@b26-ijmm-35-05-1189]). The results of the present longitudinal population-based study are thus consistent with these previous observations ([@b26-ijmm-35-05-1189],[@b31-ijmm-35-05-1189]) and validate the association of rs6929846 of *BTN2A1* with hypertension.

*BTN2A1* is a cell-surface transmembrane glycoprotein and a member of the butyrophilin superfamily of proteins. Many of these proteins regulate immune function, and polymorphisms within the coding sequences of the corresponding genes have been associated with the predisposition to inflammatory diseases ([@b32-ijmm-35-05-1189]). We have previously demonstrated that the *T* allele of rs6929846 of *BTN2A1* is associated with an increased risk of developing myocardial infarction and with an increased transcriptional activity of *BTN2A1* ([@b15-ijmm-35-05-1189]). The serum concentration of high-sensitivity C-reactive protein was significantly greater in individuals in the combined group of *CT* or *TT* genotypes for this SNP than in those with the *CC* genotype among healthy subjects without neoplastic, infectious, or inflammatory disease ([@b15-ijmm-35-05-1189],[@b33-ijmm-35-05-1189]). These observations suggest that the *T* allele of rs6929846 of *BTN2A1* may accelerate inflammatory processes.

Previous studies have suggested that chronic vascular inflammation influences BP and vascular remodeling ([@b34-ijmm-35-05-1189]--[@b37-ijmm-35-05-1189]). Systolic and diastolic BP, as well as pulse pressure were thus found to be positively associated with the plasma concentration of interleukin-6 in healthy men ([@b34-ijmm-35-05-1189]). The plasma concentration of high-sensitivity C-reactive protein was also greater in individuals with hypertension than in the controls, and it was shown to be positively associated with systolic BP and pulse pressure ([@b35-ijmm-35-05-1189]). In addition, oxidative stress and vascular inflammation have been shown to influence BP, suggesting that chronic inflammation may play a key role in the pathogenesis of hypertension ([@b36-ijmm-35-05-1189],[@b37-ijmm-35-05-1189]). In this study, we demonstrated that rs6929846 of *BTN2A1* was significantly associated with hypertension, with the minor *T* allele representing a risk factor for this condition. The enhancement of chronic inflammation by the *T* allele of rs6929846 may account for its association with hypertension, although the molecular mechanisms underlying the effects of this polymorphism on the development of hypertension remain to be elucidated.

In a previous meta-analysis of cohort studies, a reduction of 10 mmHg in systolic or 5 mmHg in diastolic BP was estimated to result in a 22--25% decrease in the incidence of coronary artery disease and a 36--41% decrease in that of stroke ([@b38-ijmm-35-05-1189]). In our longitudinal analysis, systolic, diastolic and mean BP were each increased by 1 mmHg in individuals with the *TT* genotype of rs6929846 of *BTN2A1* compared with those with the *CC* genotype. Such a difference is small at the individual level and may not have practical clinical implications. However, even small increments in BP have important effects on cardiovascular morbidity and mortality at the population level, given the high incidence of coronary artery disease, stroke and chronic kidney disease. The reduction in the mortality rate estimated for each 2-mmHg decrease in systolic BP is 4% for coronary artery disease and 6% for stroke ([@b39-ijmm-35-05-1189]). Small differences in average BP at the population level thus result in significant differences in the population mortality rate ([@b39-ijmm-35-05-1189]).

In this study, we observed that the SNPs of *PDX1*, *LLGL2* and *FAM78B* were also associated with the prevalence of hypertension, as well as with systolic BP among all individuals and individuals not taking any anti-hypertensive medication (*PDX1*), with diastolic and mean BP among individuals without anti-hypertensive medication (*LLGL2*), or with diastolic BP among individuals without anti-hypertensive medication (*FAM78B*). *FAM78B* is located at 1q24.1, which has previously been suggested to harbor susceptibility loci for hypertension ([@b40-ijmm-35-05-1189]) and type 2 diabetes mellitus ([@b41-ijmm-35-05-1189]), although the function of the gene remains unclear. *PDX1* is a transcriptional activator at several genes, including those for insulin, somatostatin, glucokinase, islet amyloid polypeptide and glucose transporter type 2 (NCBI Gene). It contributes to the early development of the pancreas and plays an important role in the glucose-dependent regulation of insulin gene expression ([@b42-ijmm-35-05-1189]). A rare frameshift variant of *PDX1* was previously found to associated with type 2 diabetes mellitus ([@b43-ijmm-35-05-1189]). We have previously demonstrated that rs146021107 of *PDX1* is significantly associated with myocardial infarction ([@b18-ijmm-35-05-1189],[@b20-ijmm-35-05-1189]), although, to the best of our knowledge, the association of *PDX1* polymorphisms with hypertension has not yet been reported. *LLGL2* plays a role in asymmetric cell division, the establishment of epithelial cell polarity and cell migration ([@b44-ijmm-35-05-1189],[@b45-ijmm-35-05-1189]). We have previously demonstrated that rs1671021 of *LLGL2* is associated with ischemic stroke ([@b16-ijmm-35-05-1189]), although, to the best of our knowledge, variants of *LLGL2* have not yet been associated with hypertension.

The present study had certain limitations: i) given that the study subjects comprised only Japanese individuals, further studies are required on other ethnic groups. ii) It is possible that rs6929846 of *BTN2A1* is in linkage disequilibrium with other polymorphisms in *BTN2A1* or in nearby genes that are actually responsible for the development of hypertension. iii) The functional relevance of rs6929846 of *BTN2A1* to the pathogenesis of hypertension remains unclear.

In conclusion, the present results suggest that *BTN2A1* is a susceptibility gene for essential hypertension in Japanese individuals. The determination of the genotype for rs6929846 may prove informative for the assessment of the genetic risk for hypertension in such individuals.
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###### 

The 13 SNPs examined in the present study.

  Chromosomal locus   Gene              dbSNP (NCBI)   Nucleotide substitution   Minor allele[a](#tfn1-ijmm-35-05-1189){ref-type="table-fn"}
  ------------------- ----------------- -------------- ------------------------- -------------------------------------------------------------
  1q24.1              *FAM78B*          rs2116519      C→T                       C
  3q28                Non-gene region   rs9846911      A→G                       G
  4q25                *ALPK1*           rs2074379      G→A (Met732Ile)           G
  4q25                *ALPK1*           rs2074380      G→A (Gly870Ser)           A
  4q25                *ALPK1*           rs2074381      A→G (Asn916Asp)           G
  4q25                *ALPK1*           rs2074388      G→A (Gly565Asp)           G
  6p22.1              *BTN2A1*          rs6929846      T→C                       T
  6q27                *THBS2*           rs8089         T→G                       G
  13q12.1             *PDX1*            rs146021107    G→- (deletion)            --
  13q34               *F7*              rs6046         G→A (Arg353Gln)           A
  17q25.1             *LLGL2*           rs1671021      G→A (Leu479Phe)           G
  19p13.2             *ILF3*            rs2569512      G→A                       A
  22q13.3             *CELSR1*          rs6007897      C→T (Ala2268Thr)          C

The minor allele in Japanese individuals was determined by the allele frequency of HapMap-JPT in dbSNP. SNPs, single nucleotide polymorphisms.

###### 

Primers, probes and other conditions for the genotyping of the 13 SNPs examined in the present study.

  Gene or locus   SNP   dbSNP         Sense primer (5′→3′)      Antisense primer (5′→3′)    Probe 1 (5′→3′)             Probe 2 (5′→3′)             Annealing   (°C) Cycles
  --------------- ----- ------------- ------------------------- --------------------------- --------------------------- --------------------------- ----------- -------------
  *FAM78B*        C→T   rs2116519     CCTGCACTGCTCTAGCTACTTC    GATCCCAATTTCAACTGTGAGATC    TCATTCCGGTCTCAGCCGCT        CCCTCATTCCGGTTTCAGCC        60          50
  3q28            A→G   rs9846911     AGTTGTGTGCCAGATTCTCCAG    TCTTCACTGAGACCTTGGGAAG      TCTCCTCTTTCAATAACAAATCTTC   AAAGTCTCCTCTTTCAGTAACAAAT   60          50
  *ALPK1*         G→A   rs2074379     TCTGCTTCTTGGTCTTCTGATTC   AGTTGGTTTCTGGAAACTCAACAA    GAAGGATGTGTGCCTATATTCTT     GATGTGTGCCCATATTCTTGGG      60          50
  *ALPK1*         G→A   rs2074380     CTCCACAGTGGATGAGGAGG      CTTACAGAGGAATTGGGGGTC       ACAAATGGGCACAGCTCTCATA      TATGAGAGCCGTGCCCATTTGT      60          50
  *ALPK1*         A→G   rs2074381     AGGACTGCACTACCACAGAGG     TGATTTCAGCCACCACACTGAG      ATCAGCCTGGAAACATGCTAAAC     AGTTTAGCATGTCTCCAGGCTG      60          50
  *ALPK1*         G→A   rs2074388     TGTGGAGACTGAGACTGAGCC     TTGCTCCAAGCACTGGAAGTC       ACTACAGCAATGATGAGGGAGC      GCTCCCTCACCATTGCTGTAG       60          50
  *BTN2A1*        T→C   rs6929846     CCAAACATGGCGACCTAGGAGA    ATCTGCCCAGGGGCACAGGC        TTTGGGAAGGTTTGCGTCTAG       TTTGGGAAGGTTTGTGTCTAGT      60          50
  *THBS2*         T→G   rs8089        AACCCAAGTGCCTTCAGAGGAT    CTCCACATAAAGTCTCATATATCAC   GATGTTCATCTCTGAGTTCCA       GATGTTCATCTCTGCGTTCCA       60          50
  *PDX1*          G→-   rs146021107   TGGCTGTGGGTTCCCTCTGAG     GATTTGGCACTGTGTGGCGTTC      CGAGCAGGGGTGGCGCC           GGCGCCACCCTGCTCGCT          60          50
  *F7*            G→A   rs6046        CGGCTACTCGGATGGCAGCA      CCAAAGTGGCCCACGGTTGC        TACCACGTGCCCCGGTAGTG        GCCACCCACTACCAGGGCA         60          50
  *LLGL2*         G→A   rs1671021     GCTCCTGGCCTCACCTTGCG      GCTGCTCTACAAACTCAGCACTG     CTGGGCACTGAAGTTCTCGTT       CCAACGAGAACCTCAGTGCC        60          50
  *ILF3*          G→A   rs2569512     ACCACCTCAACTGCAAGCTGAA    GGAATGATCCCTCTGGGAAGGT      GTGCAACTGCCAAAAACTGGT       GTGCAACTGCCAAGAACTGG        60          50
  *CELSR1*        C→T   rs6007897     GGAGACGGAGGACTCCAGCTC     CTTGCTGTCGACATCTTTGACAAG    TCTTCATGGATGGCGTCGAAT       TCTTCATGGATGGTGTCGAATC      60          50

SNPs, single nucleotide polymorphisms.

###### 

Characteristics of the study subjects: analysis of all measurements in a 5-year follow-up.

  Parameter                           Male[a](#tfn3-ijmm-35-05-1189){ref-type="table-fn"}   Female[a](#tfn3-ijmm-35-05-1189){ref-type="table-fn"}   All[a](#tfn3-ijmm-35-05-1189){ref-type="table-fn"}
  ----------------------------------- ----------------------------------------------------- ------------------------------------------------------- ----------------------------------------------------
  No. of subjects                     3352                                                  2675                                                    6027
  Age (years)                         52.5±12.5 (15,959)                                    52.5±11.9 (12,572)                                      52.5±12.2 (28,531)
  Height (cm)                         168.4±6.6 (15,550)                                    155.2±5.9 (12,373)                                      162.6±9.1 (27,923)
  Weight (kg)                         67.0±11.0 (15,548)                                    53.5±8.2 (12,373)                                       61.0±12.0 (27,921)
  Body mass index (kg/m^2^)           23.6±3.3 (15,548)                                     22.2±3.2 (12,373)                                       23.0±3.3 (27,921)
  Waist circumference (cm)            83.2±8.7 (11,817)                                     77.8±9.0 (9,541)                                        80.8±9.2 (21,358)
  Alcohol concumption (%)             67.4 (15,959)                                         26.4 (12,572)                                           49.3 (28,531)
  Current or former smoker (%)        65.0 (15,959)                                         8.5 (12,572)                                            40.1 (28,531)
  Systolic blood pressure (mmHg)      122±16 (15,541)                                       119±16 (12,370)                                         121±16 (27,911)
  Diastolic blood pressure (mmHg)     77±12 (15,541)                                        71±11 (12,370)                                          75±12 (27,911)
  Mean blood pressure (mmHg)          92±13 (15,541)                                        87±12 (12,370)                                          90±13 (27,911)
  Ocular tension (right, mmHg)        14.0±3.0 (6,132)                                      13.4±2.8 (4,886)                                        13.7±3.0 (11,018)
  Functional vital capacity (l)       3.53±0.66 (6,173)                                     2.55±0.47 (4,865)                                       3.10±0.76 (11,038)
  FEV1% (%)                           82.3±7.1 (6,168)                                      84.8±6.7 (4,865)                                        83.4±7.0 (11,033)
  Serum albumin (g/l)                 44.5±2.9 (10,332)                                     44.1±2.7 (8,510)                                        44.3±2.8 (18,842)
  Serum total cholesterol (mmol/l)    5.15±0.88 (15,121)                                    5.31±0.88 (11,887)                                      5.22±0.89 (27,008)
  Serum triglyceride (mmol/l)         1.46±1.06 (15,639)                                    1.01±0.58 (12,401)                                      1.26±0.91 (28,040)
  Serum HDL-cholesterol (mmol/l)      1.47±0.39 (15,627)                                    1.78±0.42 (12,378)                                      1.61±0.43 (28,005)
  Serum LDL-cholesterol (mmol/l)      3.19±0.81 (14,997)                                    3.18±0.79 (11,836)                                      3.18±0.80 (26,833)
  Fasting plasma glucose (mmol/l)     5.82±1.27 (15,685)                                    5.39±0.93 (12,395)                                      5.63±1.15 (28,080)
  Blood hemoglobin A1c (%)            5.78±0.74 (10,849)                                    5.64±0.54 (10,169)                                      5.71±0.66 (21,018)
  Blood urea nitrogen (mmol/l)        5.61±2.86 (8,889)                                     5.07±2.28 (8,162)                                       5.36±2.61 (17,051)
  Serum creatinine (*μ*mol/l)         88.3±116.2 (14,545)                                   63.1±82.5 (11,225)                                      77.3±103.6 (25,770)
  eGFR (ml/min/1.73 m^−2^)            77.2±18.0 (14,545)                                    80.3±17.5 (11,225)                                      78.5±17.9 (25,770)
  Serum uric acid (*μ*mol/l)          372±79 (14,368)                                       273±62 (10,900)                                         329±87 (25,268)
  Serum C-reactive protein (*μ*g/l)   1573±6428 (5,793)                                     1207±4107 (4,938)                                       1405±5486 (10,731)
  White blood cells (10^3^/*μ*l)      5.94±1.73 (12,521)                                    5.03±1.45 (9,419)                                       5.55±1.68 (21,940)
  Red blood cells (10^4^*/μl*)        461±46 (12,651)                                       415±36 (9,500)                                          441±47 (22,151)
  Hemoglobin (g/l)                    147±13 (12,651)                                       127±13 (9,501)                                          139±16 (22,152)
  Hematocrit (%)                      43.3±3.7 (12,642)                                     37.5±3.4 (9,497)                                        40.8±4.6 (22,139)
  Platelets (104/*μ*l)                23.1±5.5 (12,473)                                     23.8±6.2 (9,398)                                        23.4±5.8 (21,871)

Values in parentheses indicate the numbers of measurements taken. Quantitative data are the means ± SD. FEV1%, forced expiratory volume in 1 sec percentage; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate (ml/min/1.73 m^−2^) = 194 × \[age (years)\]^−0.287^ × \[serum creatinine (mg/dl)\]^−1.094^ × \[0.739 if female\].

###### 

Characteristics of subjects with hypertension and controls: cross-sectional analysis in March 2014.

  Parameter                           Subjects with hypertension[a](#tfn4-ijmm-35-05-1189){ref-type="table-fn"}   Controls[a](#tfn4-ijmm-35-05-1189){ref-type="table-fn"}   P-value
  ----------------------------------- --------------------------------------------------------------------------- --------------------------------------------------------- ----------
  No. of subjects                     2250                                                                        3777                                                      
  Age (years)                         61.1±10.7 (2,250)                                                           50.1±12.4 (3,777)                                         \<0.0001
  Gender (male/female, %)             62.6/37.4                                                                   51.5/48.5                                                 \<0.0001
  Height (cm)                         161.3±9.4 (2,207)                                                           163.2±9.0 (3,747)                                         \<0.0001
  Weight (kg)                         63.1±12.7 (2,205)                                                           59.7±11.6 (3,747)                                         \<0.0001
  Body mass index (kg/m^2^)           24.1±3.6 (2,205)                                                            22.3±3.1 (3,747)                                          \<0.0001
  Waist circumference (cm)            84.0±9.5 (1,986)                                                            78.5±8.5 (3,619)                                          \<0.0001
  Alcohol consumption (%)             52.0 (2,250)                                                                46.0 (3,777)                                              \<0.0001
  Current or former smoker (%)        47.7 (2,250)                                                                44.5 (3,777)                                              0.0147
  Systolic blood pressure (mmHg)      133±15 (2,200)                                                              113±11 (3,745)                                            \<0.0001
  Diastolic blood pressure (mmHg)     83±12 (2,200)                                                               70±10 (3,745)                                             \<0.0001
  Mean blood pressure (mmHg)          99±12 (2,200)                                                               84±9 (3,745)                                              \<0.0001
  Ocular tension (right, mmHg)        13.9±3.0 (722)                                                              13.3±2.9 (1,339)                                          \<0.0001
  Functional vital capacity (l)       3.12±0.80 (768)                                                             3.39±0.80 (1,475)                                         \<0.0001
  FEV1% (%)                           80.4±6.38 (768)                                                             81.7±6.6 (1,475)                                          \<0.0001
  Serum albumin (g/l)                 44.5±3.0 (1,715)                                                            44.7±2.4 (2,497)                                          0.0302
  Serum total cholesterol (mmol/l)    5.19±0.90 (2,230)                                                           5.23±0.88 (3,720)                                         0.0921
  Serum triglyceride (mmol/l)         1.43±0.96 (2,215)                                                           1.16±0.79 (3,721)                                         \<0.0001
  Serum HDL-cholesterol (mmol/l)      1.59±0.44 (2,213)                                                           1.70±0.45 (3,721)                                         \<0.0001
  Serum LDL-cholesterol (mmol/l)      3.15±0.79 (2,212)                                                           3.19±0.81 (3,720)                                         0.0632
  Fasting plasma glucose (mmol/l)     5.90±1.36 (2,238)                                                           5.40±0.96 (3,718)                                         \<0.0001
  Blood hemoglobin A1c (%)            5.84±0.78 (1,782)                                                           5.59±0.59 (2,681)                                         \<0.0001
  Blood urea nitrogen (mmol/l)        5.72±2.68 (1,691)                                                           4.86±1.23 (2,410)                                         \<0.0001
  Serum creatinine (*μ*mol/l)         88.5±127.4 (2,162)                                                          64.8±15.1 (3,414)                                         \<0.0001
  eGFR (ml/min/1.73 m^−2^)            71.2±18.3 (2,162)                                                           80.1±14.7 (3,414)                                         \<0.0001
  Serum uric acid (*μ*mol/l)          349±88 (2,139)                                                              312±81 (3,392)                                            \<0.0001
  Serum C-reactive protein (*μ*g/l)   1832±9666 (775)                                                             826±3359 (1,338)                                          0.0005
  White blood cells (10^3^/*μ*l)      5.51±1.74 (1,573)                                                           5.31±1.63 (3,034)                                         0.0001
  Red blood cells (10^4^/*μ*l)        436±48 (1,577)                                                              437±43 (3,046)                                            0.1928
  Hemoglobin (g/l)                    139±16 (1,577)                                                              137±15 (3,046)                                            0.0017
  Hematocrit (%)                      40.4±4.4 (1,576)                                                            40.1±4.2 (3,042)                                          0.0186
  Platelets (10^4^/*μ*l)              21.8±5.5 (1,557)                                                            22.6±5.3 (3,011)                                          \<0.0001

Values in parentheses indicate the numbers of measurements taken. Quantitative data are the means ± SD. eGFR, estimated glomerular filtration rate (ml/min/1.73 m^−2^) = 194 × \[age (years)\]^−0.287^ × \[serum creatinine (mg/dl)\]^−1.094^ × \[0.739 if female\]; HDL, high density lipoprotein; LDL, low density lipoprotein.

###### 

Association of polymorphisms with hypertension analyzed for 5-year longitudinal data with a generalized estimating equation.

  Gene or locus   SNP                 Genotype   Hypertension[a](#tfn6-ijmm-35-05-1189){ref-type="table-fn"}   Controls[a](#tfn6-ijmm-35-05-1189){ref-type="table-fn"}   P-value (dominant model)[b](#tfn7-ijmm-35-05-1189){ref-type="table-fn"}   P-value (recessive model)[c](#tfn8-ijmm-35-05-1189){ref-type="table-fn"}
  --------------- ------------------- ---------- ------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------- --------------------------------------------------------------------------
  *FAM78B*        rs2116519 (C→T)     *TT*       1,888 (32.3)                                                  6,649 (30.3)                                              0.3039                                                                    **0.0266**
                                      *TC*       2,959 (50.7)                                                  11,046 (50.3)                                                                                                                       
                                      *CC*       991 (17.0)                                                    4,279 (19.5)                                                                                                                        
  3q28            rs9846911 (A→G)     *AA*       5,033 (86.2)                                                  19,102 (86.9)                                             0.1629                                                                    0.1620
                                      *AG*       759 (13.0)                                                    2,756 (12.5)                                                                                                                        
                                      *GG*       46 (0.8)                                                      116 (0.5)                                                                                                                           
  *ALPK1*         rs2074379 (G→A)     *AA*       2,707 (46.4)                                                  10,004 (45.5)                                             0.7330                                                                    0.2596
                                      *AG*       2,560 (43.9)                                                  9,736 (44.3)                                                                                                                        
                                      *GG*       571 (9.8)                                                     2,234 (10.2)                                                                                                                        
  *ALPK1*         rs2074380 (G→A)     *GG*       4,905 (84.0)                                                  18,656 (84.9)                                             0.1124                                                                    0.1496
                                      *GA*       885 (15.2)                                                    3,165 (14.4)                                                                                                                        
                                      *AA*       48 (0.8)                                                      153 (0.7)                                                                                                                           
  *ALPK1*         rs2074381 (A→G)     *AA*       4,981 (85.3)                                                  18,815 (85.6)                                             0.2390                                                                    0.4732
                                      *AG*       821 (14.1)                                                    3,038 (13.8)                                                                                                                        
                                      *GG*       36 (0.6)                                                      121 (0.6)                                                                                                                           
  *ALPK1*         rs2074388 (G→A)     *AA*       2,714 (46.5)                                                  10,013 (45.6)                                             0.7043                                                                    0.2637
                                      *AG*       2,552 (43.7)                                                  9,721 (44.2)                                                                                                                        
                                      *GG*       572 (9.8)                                                     2,240 (10.2)                                                                                                                        
  *BTN2A1*        rs6929846 (T→C)     *CC*       4,484 (76.8)                                                  17,333 (78.9)                                             **0.0013**                                                                0.3602
                                      *CT*       1,275 (21.8)                                                  4,365 (19.9)                                                                                                                        
                                      *TT*       79 (1.4)                                                      276 (1.3)                                                                                                                           
  *THBS2*         rs8089 (T→G)        *TT*       4,895 (83.8)                                                  18,159 (82.6)                                             0.7407                                                                    0.9741
                                      *TG*       902 (15.5)                                                    3,615 (16.5)                                                                                                                        
                                      *GG*       41 (0.7)                                                      200 (0.9)                                                                                                                           
  *PDX1*          rs146021107 (G→-)   *GG*       1,745 (29.9)                                                  5,983 (27.2)                                              **0.0031**                                                                0.2885
                                      *G/*-      2,839 (48.6)                                                  11,049 (50.3)                                                                                                                       
                                      -/-        1,254 (21.5)                                                  4,942 (22.5)                                                                                                                        
  *F7*            rs6046 (G→A)        *GG*       5,104 (87.4)                                                  19,187 (87.3)                                             0.1478                                                                    0.8979
                                      *GA*       715 (12.2)                                                    2,693 (12.3)                                                                                                                        
                                      *AA*       19 (0.3)                                                      94 (0.4)                                                                                                                            
  *LLGL2*         rs1671021 (G→A)     *AA*       4,187 (71.7)                                                  16,353 (74.4)                                             **0.0372**                                                                0.3881
                                      *AG*       1,521 (26.1)                                                  5,223 (23.8)                                                                                                                        
                                      *GG*       130 (2.2)                                                     398 (1.8)                                                                                                                           
  *ILF3*          rs2569512 (G→A)     *GG*       2,563 (43.9)                                                  9,525 (43.3)                                              0.3765                                                                    0.2560
                                      *GA*       2,605 (44.6)                                                  10,180 (46.3)                                                                                                                       
                                      *AA*       670 (11.5)                                                    2,269 (10.3)                                                                                                                        
  *CELSR1*        rs6007897 (C→T)     *TT*       5,671 (97.1)                                                  21,303 (96.9)                                             0.6353                                                                    not determined
                                      *TC*       167 (2.9)                                                     671 (3.1)                                                                                                                           
                                      *CC*       0 (0)                                                         0 (0)                                                                                                                               

The prevalence of hypertension was compared between 2 groups (the dominant or recessive model) for each polymorphism with adjustment for age, gender, body mass index and smoking status.

Values indicate the numbers of measurements taken, with the percentages in parentheses;

dominant model: *AA* vs. *AB* + *BB* (*A*, major allele; *B*, minor allele);

recessive model (*AA* + *AB* vs. *BB*). P-values of \<0.05 are shown in bold. SNPs, single nucleotide polymorphisms.

###### 

Association of polymorphisms with systolic, diastolic, or mean BP in all individuals or individuals not taking any anti-hypertensive medication analyzed for 5-year longitudinal data with a generalized linear mixed-effect model.

  Gene                                                      SNP                 BP (mmHg)   Dominant model[a](#tfn10-ijmm-35-05-1189){ref-type="table-fn"}   P-value                Recessive model[a](#tfn10-ijmm-35-05-1189){ref-type="table-fn"}   P-value                                
  --------------------------------------------------------- ------------------- ----------- ---------------------------------------------------------------- ---------------------- ----------------------------------------------------------------- ----------------------- -------------- --------
  All individuals                                                                                                                                                                                                                                                                            
  *FAM78B*                                                  rs2116519 (C→T)                 *TT* (8,537)                                                     *TC* + *CC* (19,275)                                                                     *TT* + *TC* (2,2542)    *CC* (5,270)   
                                                                                Systolic    121.0±16.7                                                       120.4±16.1             0.3818                                                            120.7±16.5              120.1±15.7     0.5823
                                                                                Diastolic   74.9±12.5                                                        74.6±12.1              0.1260                                                            74.8±12.4               74.1±11.8      0.0823
                                                                                Mean        90.2±13.1                                                        89.9±12.6              0.1722                                                            90.1±12.9               89.4±12.2      0.1814
  *BTN2A1*                                                  rs6929846 (T→C)                 *CC* (21,817)                                                    *CT* + *TT* (5,995)                                                                      *CC* + *CT* (27,457)    *TT* (355)     
                                                                                Systolic    120.4±16.2                                                       121.2±16.7             **0.0061**                                                        120.6±16.3              121.4±15.4     0.1369
                                                                                Diastolic   74.5±12.2                                                        75.2±12.4              **0.0023**                                                        74.7±12.3               75.2±11.0      0.2483
                                                                                Mean        89.8±12.7                                                        90.5±13.0              **0.0019**                                                        90.0±12.8               90.6±11.7      0.1748
  *PDX1*                                                    rs146021107 (G→-)               *GG* (7,728)                                                     *G/*- + -/- (20,084)                                                                     *GG* + *G/*- (21,616)   -/- (6,196)    
                                                                                Systolic    121.1±17.1                                                       120.4±16.0             **0.0284**                                                        120.8±16.4              120.0±16.1     0.3884
                                                                                Diastolic   74.5±12.8                                                        74.7±12.1              0.2719                                                            74.8±12.3               74.4±12.1      0.9222
                                                                                Mean        90.1±13.3                                                        90.0±12.5              0.1029                                                            90.1±12.8               89.6±12.5      0.6821
  *LLGL2*                                                   rs1671021 (G→A)                 *AA* (20,540)                                                    *AG* + *GG* (7,272)                                                                      *AA* + *AG* (27,284)    *GG* (528)     
                                                                                Systolic    120.4±16.2                                                       121.2±16.6             0.1943                                                            120.6±16.3              121.6±16.1     0.9056
                                                                                Diastolic   74.5±12.2                                                        75.2±12.4              0.1280                                                            74.7±12.3               75.8±12.7      0.4665
                                                                                Mean        89.8±12.7                                                        90.5±12.9              0.1315                                                            90.0±12.8               91.1±12.8      0.7203
  Individuals not taking any anti-hypertensive medication                                                                                                                                                                                                                                    
  *FAM78B*                                                  rs2116519 (C→T)                 *TT* (8,132)                                                     *TC* + *CC* (18,370)                                                                     *TT* + *TC* (2,1459)    *CC* (5,043)   
                                                                                Systolic    120.5±16.7                                                       119.9±16.0             0.2563                                                            120.2±16.4              119.7±15.6     0.5041
                                                                                Diastolic   74.6±12.5                                                        74.4±12.1              0.2039                                                            74.6±12.4               73.9±11.7      0.0495
                                                                                Mean        89.9±13.0                                                        89.6±12.6              0.1948                                                            89.8±12.9               89.1±12.1      0.1248
  *BTN2A1*                                                  rs6929846 (T→C)                 *CC* (20,807)                                                    *CT* + *TT* (5,695)                                                                      *CC* + *CT* (26,163)    *TT* (339)     
                                                                                Systolic    120.0±16.1                                                       120.7±16.6             **0.0017**                                                        120.1±16.3              120.8±15.3     0.1734
                                                                                Diastolic   74.3±12.2                                                        75.0±12.4              **0.0008**                                                        74.4±12.3               75.0±10.8      0.2059
                                                                                Mean        89.5±12.7                                                        90.2±13.0              **0.0005**                                                        89.7±12.7               90.3±11.5      0.1678
  *PDX1*                                                    rs146021107 (G→-)               *GG* (7,328)                                                     *G/*- + -/- (19,174)                                                                     *GG* + *G/*- (20,580)   -/- (5,922)    
                                                                                Systolic    120.6±17.1                                                       120.0±15.9             **0.0132**                                                        120.3±16.3              119.5±16.0     0.2565
                                                                                Diastolic   74.2±12.8                                                        74.5±12.0              0.3963                                                            74.5±12.3               74.2±12.1      0.8832
                                                                                Mean        89.7±13.3                                                        89.7±12.5              0.1081                                                            89.8±12.8               89.3±12.5      0.7018
  *LLGL2*                                                   rs1671021 (G→A)                 *AA* (19,569)                                                    *AG* + *GG* (6,933)                                                                      *AA* + *AG* (26,005)    *GG* (497)     
                                                                                Systolic    119.9±16.2                                                       120.7±16.5             0.0891                                                            120.1±16.3              121.4±16.1     0.6847
                                                                                Diastolic   74.2±12.2                                                        75.0±12.4              **0.0468**                                                        74.4±12.2               75.7±12.7      0.2512
                                                                                Mean        89.5±12.7                                                        90.2±12.9              **0.0471**                                                        89.6±12.7               90.9±12.80     0.3889

Systolic, diastolic, or mean BP was compared between 2 groups (the dominant or recessive model) for each polymorphism with adjustment for age, gender, body mass index and smoking status.

Values in parentheses indicate the numbers of measurements taken. Data for BP are the means ± SD. P-values of \<0.05 are shown in bold. BP, blood pressure. SNPs, single nucleotide polymorphisms.
